Noncoding RNAs as circulating biomarkers in osteosarcoma patients.

Autor: Botti G; Scientific Direction, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, Naples, Italy., Giordano A; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology College of Science and Technology, Temple University, Philadelphia, Pennsylvania.; Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy., Feroce F; Pathology Unit, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, Naples, Italy., De Chiara AR; Pathology Unit, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, Naples, Italy., Cantile M; Pathology Unit, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, Naples, Italy.
Jazyk: angličtina
Zdroj: Journal of cellular physiology [J Cell Physiol] 2019 Nov; Vol. 234 (11), pp. 19249-19255. Date of Electronic Publication: 2019 Apr 29.
DOI: 10.1002/jcp.28744
Abstrakt: Noncoding RNAs (ncRNAs) identify a large family of RNAs that do not encode proteins and represent an important group of tumor biomarkers, directly involved in the process of tumor pathogenesis and progression. Many of them have also been identified in biological fluids of patients with cancer, especially blood, suggesting their role as an emerging class of circulating biomarkers. Many ncRNAs, both miRNAs and lncRNAs, are deregulated in sarcoma tissues, with the most consistent data in osteosarcomas. In patients with osteosarcoma, the role of ncRNAs as circulating biomarkers is taking enormous value, above all for their ability to vary expression levels during disease progression and in response to therapy. In this mini-review, we summarize the main studies supporting the role of circulating ncRNAs in monitoring disease status in patients with osteosarcoma.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: